TY - JOUR
T1 - Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project
AU - Fight Retinal Blindness Study Grp
AU - Daien, Vincent
AU - Vuong Nguyen, null
AU - Morlet, Nigel
AU - Arnold, Jennifer J.
AU - Essex, Rohan W.
AU - Young, Stephanie
AU - Hunyor, Alex
AU - Gillies, Mark C.
AU - Barthelmes, Daniel
PY - 2018/6/1
Y1 - 2018/6/1
N2 - PURPOSE: To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).DESIGN: Retrospective, matched case-control study.METHODS: We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.RESULTS: We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P <.001) 12 months after surgery; 26.0% had gained " lines and 1.6% had lost >= 3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P =.018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P =.506 and P =.316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained >= 15 letters-compared with eyes that gained 0.14 letters (40.2 [21.4] vs 62.1 [15.1], P <.001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining >= 15 or 0-14 letters respectively, P =.023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.CONCLUSIONS: We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible. (C) 2018 Elsevier Inc. All rights reserved.
AB - PURPOSE: To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).DESIGN: Retrospective, matched case-control study.METHODS: We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.RESULTS: We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P <.001) 12 months after surgery; 26.0% had gained " lines and 1.6% had lost >= 3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P =.018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P =.506 and P =.316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained >= 15 letters-compared with eyes that gained 0.14 letters (40.2 [21.4] vs 62.1 [15.1], P <.001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining >= 15 or 0-14 letters respectively, P =.023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.CONCLUSIONS: We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible. (C) 2018 Elsevier Inc. All rights reserved.
KW - ENDOTHELIAL GROWTH-FACTOR
KW - POSTERIOR VITREOUS DETACHMENT
KW - INTRAVITREAL BEVACIZUMAB
KW - PSEUDOPHAKIC EYES
KW - INJECTIONS
KW - THERAPY
KW - RISK
U2 - 10.1016/j.ajo.2018.03.012
DO - 10.1016/j.ajo.2018.03.012
M3 - Article
SN - 0002-9394
VL - 190
SP - 50
EP - 57
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -